类风湿关节炎患者接受奥洛珠单抗治疗期间的miRNA表达分析
Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment.
作者信息
Bure Irina V, Mikhaylenko Dmitry S, Kuznetsova Ekaterina B, Alekseeva Ekaterina A, Bondareva Kristina I, Kalinkin Alexey I, Lukashev Alexander N, Tarasov Vadim V, Zamyatnin Andrey A, Nemtsova Marina V
机构信息
Institute of Molecular Medicine, Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya str., 8-2, 119992 Moscow, Russia.
Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechye str. 1, 115478 Moscow, Russia.
出版信息
J Pers Med. 2020 Oct 31;10(4):205. doi: 10.3390/jpm10040205.
Rheumatoid arthritis (RA) is the most common autoimmune disease worldwide. Epigenetic alternations of microRNAs (miRNAs) can contribute to its pathogenesis and progression. As the first line therapy with DMARDs is not always successful, other drugs and therapeutic targets should be applied. This study aims to measure the expression level of plasma miRNAs in RA patients treated with olokizumab and to evaluate their potential as prognostic biomarkers. The expression of 9 miRNAs was quantified in 103 RA patients before treatment and at weeks 12 and 24 of olokizumab therapy by reverse transcription-polymerase chain reaction (RT-PCR) assay and analyzed in groups of responders and non-responders. Almost all miRNAs changed their expression during therapy. The ROC curve analysis of the most prominent of them together with consequent univariate and multivariate regression analysis revealed statistically significant associations with the olokizumab therapy efficiency scores for miR-26b, miR-29, miR-451, and miR-522. Therefore, these miRNAs might be a potential therapeutic response biomarker.
类风湿关节炎（RA）是全球最常见的自身免疫性疾病。微小RNA（miRNA）的表观遗传改变可能有助于其发病机制和进展。由于使用改善病情抗风湿药（DMARDs）作为一线治疗并不总是成功，应应用其他药物和治疗靶点。本研究旨在测量接受奥洛珠单抗治疗的RA患者血浆miRNA的表达水平，并评估其作为预后生物标志物的潜力。通过逆转录-聚合酶链反应（RT-PCR）测定法对103例RA患者治疗前以及奥洛珠单抗治疗第12周和第24周时9种miRNA的表达进行定量，并在反应者和无反应者组中进行分析。几乎所有miRNA在治疗期间都改变了其表达。对其中最突出的miRNA进行ROC曲线分析，并随后进行单变量和多变量回归分析，结果显示miR-26b、miR-29、miR-451和miR-522与奥洛珠单抗治疗效率评分存在统计学上的显著关联。因此，这些miRNA可能是潜在的治疗反应生物标志物。
Zotero 插件